-
公开(公告)号：US20210171477A1
公开(公告)日：2021-06-10
申请号：US16632849
申请日：2018-07-23
发明人： Luigi FRANCHI , Shomir GHOSH , Gary GLICK , Jason KATZ , Anthony William OPIPARI, Jr. , William ROUSH , Hans Martin SEIDEL , Dong-Ming SHEN , Shankar VENKATRAMAN , David Guenther WINKLER
IPC分类号： C07D277/36 , C07C307/06 , C07D307/64 , C07D333/34 , C07D263/46 , C07D213/71 , C07D231/18 , C07D487/04 , C07D215/36 , C07D317/62 , C07D307/79 , C07D239/26
摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.
-
公开(公告)号：US20210230129A1
公开(公告)日：2021-07-29
申请号：US16632850
申请日：2018-07-23
发明人： Luigi FRANCHI , Shomir GHOSH , Gary GLICK , Jason KATZ , Anthony William OPIPARI, Jr. , William ROUSH , Hans Martin SEIDEL , Dong-Ming SHEN , Shankar VENKATRAMAN , David Guenther WINKLER
IPC分类号： C07D265/30 , C07D333/34 , C07C381/10 , C07D277/36 , C07D263/46 , C07D231/12 , C07D239/26 , C07D317/50 , C07D215/06 , C07D209/26 , C07D211/78 , C07D239/36 , C07D261/08 , C07D417/12 , C07D409/12 , C07D401/12 , A61P1/00 , A61P11/00 , A61P19/08 , A61P35/00
摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.
-
公开(公告)号：US20200087270A1
公开(公告)日：2020-03-19
申请号：US16572528
申请日：2019-09-16
发明人： Luigi FRANCHI , Shomir GHOSH , Gary GLICK , Jason KATZ , Anthony William OPIPARI, Jr. , William ROUSH , Hans Martin SEIDEL , Dong-Ming SHEN , Shankar VENKATRAMAN , David Guenther WINKLER
IPC分类号： C07D277/36 , C07D307/64 , C07D333/34
摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
-
-
搜索结果
3 条记录 (耗时 0.022 秒)
